Overview

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Status:
Active, not recruiting

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

Single arm phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal site, either de novo, or relapsed following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma).

Phase:

Phase 2

Details

Lead Sponsor:

International Extranodal Lymphoma Study Group (IELSG)

Treatments:

Chlorambucil
Rituximab